Literature DB >> 9790631

Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator.

M Ohji1, Y Saito, A Hayashi, J M Lewis, Y Tano.   

Abstract

OBJECTIVE: To assess the efficacy and complications of intravitreal injection of perfluoropropane gas for displacement of subretinal hemorrhage (SRH), without the use of tissue plasminogen activator. PATIENTS AND METHODS: Pure perfluoropropane gas (0.4-0.5 mL) was injected into the vitreous cavity in 5 patients with SRH involving the fovea because of age-related macular degeneration (4 eyes) or ruptured retinal arterial macroaneurysm (1 eye). The patients were instructed to maintain a prone position.
RESULTS: Visual acuity ranged from 20/300 to 20/2000 before gas injection. On the day after gas injection, SRH was dramatically displaced in 3 eyes and slightly displaced with a reduction in the thickness of subfoveal hemorrhage in the remaining 2 eyes. Final visual acuity improved in all cases, ranging from 20/15 to 20/220. Three eyes had a final visual acuity of 20/50 or better. Vitreous hemorrhage caused by migration of SRH into the vitreous cavity and retinal detachment each occurred in 1 eye, and both complications were successfully treated by vitrectomy.
CONCLUSIONS: Gas injected into the vitreous cavity can displace SRH without the use of tissue plasminogen activator in some cases. Visual acuity after gas injection may be improved, making this treatment an alternative to evacuation of SRH with vitrectomy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790631     DOI: 10.1001/archopht.116.10.1326

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  41 in total

1.  Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.

Authors:  Jost Hillenkamp; Vladimir Surguch; Carsten Framme; Veit-Peter Gabel; Helmut G Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-11       Impact factor: 3.117

Review 2.  Clinical characteristics and current treatment of age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Ivana K Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-03       Impact factor: 6.915

3.  Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage.

Authors:  Y Oshima; M Ohji; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

4.  Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.

Authors:  Ikuko Kachi; Tsutomu Yasukawa; Aki Kato; Noriaki Takase; Hiroshi Morita; Ayae Kubota; Yoshio Hirano; Akiyoshi Uemura; Yuichiro Ogura
Journal:  Jpn J Ophthalmol       Date:  2016-02-26       Impact factor: 2.447

5.  Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.

Authors:  Takeshi Mizutani; Tsutomu Yasukawa; Yuya Ito; Ayae Takase; Yoshio Hirano; Munenori Yoshida; Yuichiro Ogura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-29       Impact factor: 3.117

6.  Visual prognosis of eyes with submacular hemorrhage associated with exudative age-related macular degeneration.

Authors:  Naoko Ueda-Arakawa; Akitaka Tsujikawa; Kenji Yamashiro; Sotaro Ooto; Hiroshi Tamura; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2012-10-04       Impact factor: 2.447

7.  Retinal sensitivity after displacement of submacular hemorrhage due to polypoidal choroidal vasculopathy: effectiveness and safety of subretinal tissue plasminogen activator.

Authors:  Shuhei Kimura; Yuki Morizane; Ryo Matoba; Mio Hosokawa; Yusuke Shiode; Masayuki Hirano; Shinichiro Doi; Shinji Toshima; Kosuke Takahashi; Mika Hosogi; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2017-08-23       Impact factor: 2.447

8.  Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.

Authors:  Luis Arias; Jordi Monés
Journal:  Clin Ophthalmol       Date:  2010-02-18

9.  Treatment of massive subretinal hematoma associated with age-related macular degeneration using vitrectomy with intentional giant tear.

Authors:  Eisuke Isizaki; Seita Morishita; Takaki Sato; Masanori Fukumoto; Hiroyuki Suzuki; Teruyo Kida; Mari Ueki; Tsunehiko Ikeda
Journal:  Int Ophthalmol       Date:  2015-07-28       Impact factor: 2.031

10.  Visual outcome after vitreous, sub-internal limiting membrane, and/or submacular hemorrhage removal associated with ruptured retinal arterial macroaneurysms.

Authors:  Hideo Nakamura; Kazuhisa Hayakawa; Shoichi Sawaguchi; Takeshi Gaja; Noriyoshi Nagamine; Kodo Medoruma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.